Evidence map›Paper›PMID 36246186›Full record

ArticleOphthalmology science2022

Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018: The LANDSCAPE Study.

Catherine P Creuzot-Garcher, Mayer Srour, Florian Baudin, Vincent Daien, Corinne Dot, Sylvia Nghiem-Buffet, Jean-Francois Girmens, Nicolas Coulombel, Anne Ponthieux, Cecile Delcourt

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Complement inhibitors for age-related macular degeneration.The Cochrane database of systematic reviews · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 1 country.

Catherine P Creuzot-GarcherDepartment of Ophthalmology, University Hospital, Dijon, France.
Mayer SrourDepartment of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Université de Paris Est Créteil, Créteil, France.
Florian BaudinDepartment of Ophthalmology, University Hospital, Dijon, France.
Vincent DaienDepartment of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France.
Corinne DotDepartment of Ophthalmology, Desgenettes Military Hospital, Lyon, France.
Sylvia Nghiem-BuffetCentre d'imagerie et de laser, Paris, France.
Jean-Francois GirmensDepartment of Ophthalmology, INSERM-DGOS CIC 1423, CHNO des Quinze-Vingts, Paris, France.
Nicolas CoulombelIQVIA France, La Défense, France.
Anne PonthieuxNovartis Pharma SAS, Rueil-Malmaison, Malmaison, France.
Cecile DelcourtUniversité de Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, Team LEHA, Bordeaux, France.
Centre Ophtalmologique d'Imagerie et de Laser · FRCHU Dijon Bourgogne · FRHôpital d'instruction des Armées Desgenettes · FRHôpital Gui de Chauliac · FRInserm · FRIQVIA (France) · FRNovartis (France) · FRUniversité de Bordeaux · FRUniversité de Bourgogne · FRUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to estimate the incidence and prevalence of neovascular age-related macular degeneration (nAMD) in the French population between 2008 and 2018. Design: This was a retrospective, longitudinal population study using health care consumption data from the Système National des Données de Santé (SNDS; the French National Health Information Database), which covers approximately 99% of the French population. Participants: We identified individuals treated for nAMD from the French population 50 years of age and older. Identification criteria were nAMD diagnosis or reimbursement of nAMD treatments (anti-vascular endothelial growth factor intravitreal injection or dynamic phototherapy with verteporfin). Exclusion criteria were high myopia, diagnosis of other retinal diseases, and other treatments for macular diseases (dexamethasone implant, laser therapy, etc.). Methods: We calculated incidence and prevalence based on the age-matched general population in France. Adjustment for age and sex was also performed for incidence. Main Outcome Measures: Incidence and prevalence of nAMD in the French population between 2008 and 2018. Results: Between 2008 and 2018, we identified 342 961 patients with nAMD (67.5% women). Mean ± standard deviation age at nAMD diagnosis or first treatment increased from 78.8 ± 8.1 years in 2008 to 81.2 ± 7.9 years in 2018. In 2018, annual incidence was 0.149% and prevalence was 1.062% for the French population 50 years of age or older. Incidence was stable over the 10-year period. Annual incidence increased with age (0.223%, 0.380%, and 0.603% in those 60 years of age or older, 70 years of age or older, and 80 years of age or older, respectively), with similar trends for prevalence. No major differences were observed among the 14 regions of France for incidence or prevalence. Neovascular age-related macular degeneration incidence in 2018 was not impacted by the availability of primary or ophthalmology care in patients' localities. Conclusions: The LANDSCAPE study provides exhaustive nationwide data on incidence and prevalence of nAMD in France over a 10-year period.

Indexed as

Age-related macular degenerationAMD, age-related macular degenerationFranceICD-10, International Classification of Diseases, Tenth RevisionIncidencenAMD, neovascular age-related macular degenerationNeovascularPrevalenceSNDS, Système National des Données de Santé (National Health Information Database)VEGF, vascular endothelial growth factor

Identifiers

PMID36246186
PMCPMC9562296
OpenAlexW4207025666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.